NCT06632990View on ClinicalTrials.gov

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

April 3, 2025

Study Completion Date

October 15, 2025

Conditions
Drug Drug Interaction (DDI)
Interventions
DRUG

BMS-984923

oral capsules once or twice daily

DRUG

Midazolam

midazolam, oral, 2mg administered before study drug and after study drug

DRUG

Caffeine

Caffeine, oral, 100mg administered before study drug and after study drug

DRUG

dextromethorphan

dextromethorphan, oral, 30mg administered before study drug and after study drug

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

Sponsors

Lead Sponsor

Allyx Therapeutics
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Allyx Therapeutics

INDUSTRY

NCT06632990 - A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates | Biotech Hunter | Biotech Hunter